

## Parker, Bryan

---

**From:** Parker, Bryan  
**Sent:** Thursday, September 06, 2018 3:12 PM  
**To:** 'TARQY@sbcglobal.net'  
**Subject:** NRC Request for Additional Info  
**Attachments:** Spectron -01MD lic RAI 609116.docx

Hey Greg,

After our discussion and upon further review, I decided I need some additional information on these "newer" isotopes and how you will be handling them, etc. So please see the attached Request for Additional Information.

Please refer to the Control No. (CN609116) and indicate it is as "Additional Information".

Then, please provide a **signed letter** and attach it all as a PDF file to an email back to me.

If you have any questions, please let me know.

Thanks.  
Bryan

*Bryan A. Parker*  
Senior Health Physicist  
USNRC Region III  
[bryan.parker@nrc.gov](mailto:bryan.parker@nrc.gov)  
678-828-7050  
630-515-1078 (fax)



**Request for Additional Information**

**Spectron mrc, LLC - South Bend, IN (CN609116)**

**License No. 13-32726-01MD**

**Docket No. 030-38044**

- 1) With regard to Item D of your letter dated June 18, 2018, please describe the intended purpose(s) and proposed authorized use(s) of lutetium-177 (Lu-177). Also, please provide justification for the 15 curie possession limit requested.

Please also indicate how the material will be received, the form(s) it will be used in, and further describe any special handling procedures you plan to employ, to include need for bioassay, dosimetry, and breathing zone and effluent monitoring.

- 2) With regard to Item E of your letter dated June 18, 2018, please describe the intended purpose(s) and proposed authorized use(s) of actinium-225 (Ac-225). Also, please provide justification for the 300 millicurie possession limit requested.

Please also indicate how the material will be received, the form(s) it will be used in, and further describe any special handling procedures you plan to employ, to include need for bioassay, dosimetry, and breathing zone and effluent monitoring.

- 3) With regard to Item G of your letter dated June 18, 2018, please describe the intended purpose(s) and proposed authorized use(s) of astatine-211 (At-211). Also, please provide justification for the 300 millicurie possession limit requested.

Please also indicate how the material will be received, the form(s) it will be used in, and further describe any special handling procedures you plan to employ, to include need for bioassay, dosimetry, and breathing zone and effluent monitoring.

- 4) With regard to Item H of your letter dated June 18, 2018, please describe the intended purpose(s) and proposed authorized use(s) of zirconium-89 (Zr-89). Also, please provide justification for the 2 curie possession limit requested.

Please also indicate how the material will be received, the form(s) it will be used in, and further describe any special handling procedures you plan to employ, to include need for bioassay, dosimetry, and breathing zone and effluent monitoring.